14 Times Volume Spurt Alert: Hyderabad-based pharma penny stock under Rs 50, jumps 14% on September 12

Shares of Sigachi Industries Ltd, a Small-Cap pharmaceutical company, continued their upward momentum on Friday as they surged 14 per cent to Rs 43.22 in intra-day trade on the BSE. This sharp move comes after a strong rally on Thursday, taking the stock’s two-day gain to 37 per cent.

At 11:32 AM, the stock was trading 13 per cent higher at Rs 42.77 compared with a 0.5 per cent rise in the BSE Sensex, indicating strong outperformance. The rally was accompanied by heavy trading volumes, with nearly 130 million equity shares — representing 34 per cent of the company’s total equity — changing hands across exchanges. Of this, around 112 million shares were traded on the NSE, while 18 million were transacted on the BSE.

The stock has been witnessing strong investor interest since hitting its 52-week low of Rs 30.54 on August 18, 2025. On the other hand, it had touched a 52-week high of Rs 60.38 on September 23, 2024. With the recent move, the stock is now trading closer to its support levels and remains significantly below its 52-week high.

Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.

The company opened an R&D Centre in Hyderabad on July 28, 2025, to boost its scientific capabilities. The centre will focus on developing high-value Active Pharmaceutical Ingredients (APIs) for global markets. A team of 32-35 scientists will manage the entire API development process, from initial research to commercialisation and regulatory filings. The new facility will help Sigachi expedite product development for regulated markets, targeting key therapeutic areas and enhancing its competitive edge.

According to Quarterly Results, the company reported net sales of Rs 128 crore and net loss of Rs 101 crore. In its annual results, revenue increased by 22 per cent to Rs 488.24 crore, EBITDA increased by 36 per cent to Rs 120.50 crore and consolidated PAT increased by 22 per cent to Rs 70.46 crore in FY25 compared to FY24.

Disclaimer: The article is for informational purposes only and not investment advice.